IsoPSA Assay
Cleveland Diagnostics, Inc. · Decision date Jul 28, 2026
What did the FDA approve?
FDA records P200048/S001 as a supplement to PMA P200048, with the supplement type “Real-Time Process”. The recorded decision is approval, dated Jul 28, 2026.
FDA approval order statement
extension of the shelf-life of the IsoPSA Controls
- Regulatory pathway
- PMA supplement
- Supplement type
- Real-Time Process
- Clinical specialty
- Immunology
- Decision date
- Jul 28, 2026
- FDA change category
- Labeling Change - Indications/instructions/shelf life/tradename
Regulatory record facts
- Identifier
- P200048/S001
- Regulatory pathway
- PMA supplement
- Applicant
- Cleveland Diagnostics, Inc.
- Product code
- QRF
- Decision code
- APPR
- Decision date
- Jul 28, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Multi-analyte test system with algorithmic analysis for detection of prostate cancer.
- Applicant
- Cleveland Diagnostics, Inc.
- Product code
- QRF
- FDA device class
- 3
For the original device and its historical approval scope, see PMA P200048. Subsequent supplements may change the device or its indications.
FDA decision timeline
P200048 · Original PMA
IsoPSA Assay
P200048/S001 received
Application receipt date recorded by FDA.
P200048/S001 · FDA decision
Real-Time Process
Timeline entries are records held by MedtechLedger for P200048. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P200048
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
IsoPSA AssayP200048 | Cleveland Diagnostics, Inc. | PMA approval | Nov 28, 2025 | FDA |
Explore the linked device profile
Other records with product code QRF
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
4Kscore TestP190022/S003 | Opko Health, Inc. | PMA supplement | Jul 25, 2025 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
FDA describes the real-time supplement process as a review route for minor changes to a device, including certain design, software, sterilization or labeling changes.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Cleveland Diagnostics, Inc.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 3615 Superior Ave., Suite 4407b, Cleveland, OH, 44114
Sources and methodology
- Original FDA record: P200048/S001
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 21, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records
